Studies have shown that in breast cancer in situ, paclitaxel monotherapy increases the proportion of CAFs in the TME, while inhibition of LSD1 (Phenelzine) alone or combined chemotherapy reduces CAFs infiltration significantly 78. Here, KDM1A is linked to breast carcinoma.